Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Parnetti

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
European Journal of Neurology|December 31, 2009
Cerebrospinal fluid biomarkers and white matter lesions: can we know more?L Parnetti
Clinical Pharmacokinetics|August 1, 1995
Clinical pharmacokinetics of drugs for Alzheimer's diseaseL Parnetti
Revue Neurologique|October 21, 1999
Pathophysiology of vascular dementia and white matter changesL Parnetti
Journal of Neurology|April 29, 2000
Therapeutic options in dementiaL Parnetti
Mechanisms of Ageing and Development|November 18, 2005
Early detection of dementia in clinical practiceS Giaquinto, L Parnetti
Cerebrovascular Diseases (Basel, Switzerland)|November 9, 2000
Atrial fibrillation and strokeL Parnetti, V Gallai
Mechanisms of Ageing and Development|October 9, 2001
Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical dataL Parnetti, F Amenta, V Gallai
Gerontology|January 1, 1986
Chronic cerebrovascular disorders: hemorheological and psychobehavioral aspectsL Parnetti, G Ciuffetti, U Senin
Aging (Milan, Italy)|August 1, 1997
Role of homocysteine in age-related vascular and non-vascular diseasesL Parnetti, T Bottiglieri, D Lowenthal
Drugs|May 1, 1997
Cognitive enhancement therapy for Alzheimer's disease. The way forwardL Parnetti, U Senin, P Mecocci
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
European Journal of Neurology|December 31, 2009
Cerebrospinal fluid biomarkers and white matter lesions: can we know more?L Parnetti
Clinical Pharmacokinetics|August 1, 1995
Clinical pharmacokinetics of drugs for Alzheimer's diseaseL Parnetti
Revue Neurologique|October 21, 1999
Pathophysiology of vascular dementia and white matter changesL Parnetti
Journal of Neurology|April 29, 2000
Therapeutic options in dementiaL Parnetti
Mechanisms of Ageing and Development|November 18, 2005
Early detection of dementia in clinical practiceS Giaquinto, L Parnetti
Cerebrovascular Diseases (Basel, Switzerland)|November 9, 2000
Atrial fibrillation and strokeL Parnetti, V Gallai
Mechanisms of Ageing and Development|October 9, 2001
Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical dataL Parnetti, F Amenta, V Gallai
Gerontology|January 1, 1986
Chronic cerebrovascular disorders: hemorheological and psychobehavioral aspectsL Parnetti, G Ciuffetti, U Senin
Aging (Milan, Italy)|August 1, 1997
Role of homocysteine in age-related vascular and non-vascular diseasesL Parnetti, T Bottiglieri, D Lowenthal
Drugs|May 1, 1997
Cognitive enhancement therapy for Alzheimer's disease. The way forwardL Parnetti, U Senin, P Mecocci
Pageof 12